Bioxcel Therapeutics Inc (BTAI) Stock Price, Quote & News

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Biotechnology

Sector: Healthcare

Phone: 475 238 6837

Website: www.bioxceltherapeutics.com

Address:

555 Long Wharf Drive, 12th Floor, New Haven, United States

kellymone2 Oct. 7 at 8:29 AM

$NCNA +78% since then. And now it's time for $BTAI

0 · Reply

Dan2020 Oct. 7 at 1:56 AM

$BTAI what's the story on this one guys? new here

0 · Reply

Zbrodt Oct. 7 at 1:43 AM

$BTAI pretty hard to sit and hold this stock when you have the mkt rolling higher on a daily basis. Whats the catalyst you guys? I guess this is just has to be a small piece of your portfolio and put it to the side and just wait.

1 · Reply

Zkoko_Bio Oct. 7 at 12:23 AM

$BTAI They'll be out of cash this month or next

1 · Reply

mjk49 Oct. 6 at 10:10 PM

$BTAI Want to see how this reacts if market corrects sometime soon…no change until any news.. this stock is purely news driven and the shorts/algos play with it well..

0 · Reply

LiquidThetaLEAPS Oct. 6 at 6:31 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $BTAI Current Share Price: $2.60 Contracts: $BTAI January 16, 2026 $3 Calls Scale in: $0.14- $0.17 Scale out: $0.21-$0.27 Can Easily Capture: 60% ROI Blended DTE: 102 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Nuevoempresario Oct. 6 at 6:14 PM

$BTAI anyone have a target price and any ideas of its price ?

2 · Reply

FoobarSwopey Oct. 6 at 6:00 PM

$BTAI I keep saying that they have an AI generated pulse with this stock. They never deviate much above $2.55 to $2.60 and if you see it go above that, don't get your hopes up for an extended rally. They are absolute thieves with all of us.

1 · Reply

tommy45 Oct. 6 at 5:50 PM

$BTAI have around 20k here just waiting for news soon guys right now 2.48 to 2.69 trading range gl rest of the week

2 · Reply

tommy45 Oct. 6 at 5:29 PM

$BTAI most experts has a 10 dollar price target on BTAI so oversold with the news that is coming it's crazy gl

1 · Reply

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

Sep 10, 2025, 6:41 PM EDT - 26 days ago

BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)

Sep 10, 2025, 3:08 PM EDT - 26 days ago

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

Sep 10, 2025, 6:30 AM EDT - 26 days ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 4, 2025, 7:00 AM EDT - 4 weeks ago

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 12:01 PM EDT - 5 weeks ago

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

Aug 27, 2025, 8:00 AM EDT - 5 weeks ago

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 27, 2025, 7:29 AM EDT - 5 weeks ago

BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:00 AM EDT - 5 weeks ago

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 26, 2025, 4:00 PM EDT - 5 weeks ago

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Aug 19, 2025, 7:00 AM EDT - 6 weeks ago

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 18, 2025, 7:00 AM EDT - 7 weeks ago

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 13, 2025, 7:00 AM EDT - 7 weeks ago

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 12, 2025, 7:55 AM EDT - 7 weeks ago

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 11, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

Aug 1, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 21, 2025, 7:00 AM EDT - 2 months ago

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Jul 1, 2025, 7:00 AM EDT - 3 months ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 4 months ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 7:00 AM EDT - 4 months ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 12, 2025, 7:00 AM EDT - 5 months ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 27, 2025, 7:00 AM EDT - 6 months ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 7 months ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 4, 2025, 4:15 PM EST - 7 months ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 7 months ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 7:00 AM EST - 7 months ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Feb 28, 2025, 7:00 AM EST - 7 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2025, 7:00 AM EST - 8 months ago

BioXcel Therapeutics Announces Reverse Stock Split

Nov 22, 2024, 8:16 AM EST - 11 months ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 21, 2024, 4:47 PM EST - 11 months ago

BioXcel Therapeutics Announces Proposed Public Offering

Nov 14, 2024, 9:07 AM EST - 11 months ago

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:00 AM EST - 11 months ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Sep 19, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Sep 5, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 9, 2024, 9:48 PM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript

Jul 16, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

May 28, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

May 21, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

May 9, 2024, 9:53 AM EDT - 1 year ago

BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:30 AM EDT - 1 year ago

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Apr 22, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Apr 10, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia

Mar 25, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

Mar 15, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

kellymone2 Oct. 7 at 8:29 AM

$NCNA +78% since then. And now it's time for $BTAI

0 · Reply

Dan2020 Oct. 7 at 1:56 AM

$BTAI what's the story on this one guys? new here

0 · Reply

Zbrodt Oct. 7 at 1:43 AM

1 · Reply

Zkoko_Bio Oct. 7 at 12:23 AM

$BTAI They'll be out of cash this month or next

1 · Reply

mjk49 Oct. 6 at 10:10 PM

$BTAI Want to see how this reacts if market corrects sometime soon…no change until any news.. this stock is purely news driven and the shorts/algos play with it well..

0 · Reply

LiquidThetaLEAPS Oct. 6 at 6:31 PM

0 · Reply

Nuevoempresario Oct. 6 at 6:14 PM

$BTAI anyone have a target price and any ideas of its price ?

2 · Reply

FoobarSwopey Oct. 6 at 6:00 PM

1 · Reply

tommy45 Oct. 6 at 5:50 PM

$BTAI have around 20k here just waiting for news soon guys right now 2.48 to 2.69 trading range gl rest of the week

2 · Reply

tommy45 Oct. 6 at 5:29 PM

$BTAI most experts has a 10 dollar price target on BTAI so oversold with the news that is coming it's crazy gl

1 · Reply

Hillboys Oct. 6 at 4:59 PM

$BTAI

0 · Reply

mattb211 Oct. 6 at 4:37 PM

$BTAI 7 bucks incoming

1 · Reply

Bossbaby14 Oct. 6 at 4:28 PM

$SOPA she’s for sure hitting five dollars either today or by tomorrow watch it $AIRE $BTAI $DFLI

0 · Reply

Olarin_viisas Oct. 6 at 3:36 PM

$BTAI It's crazy how unnoticed this went: Millennium Management has just quietly bought over 20% of Bioxcel. So, all of you who think with their 500 shares how bad investment this is, you must feel sympathy for Mr Israel Englander and his companies who are stuck with more than 4 million shares. Or... they know something. https://ir.bioxceltherapeutics.com/node/13471/html

4 · Reply

FoobarSwopey Oct. 6 at 2:51 PM

$BTAI it's not going above $3.00 for a while, if ever. If you do see it go above $3, don't wait, sell it as quickly as you can. I'll never invest in it again, if I'm lucky enough to see it hit $3.05 or even $3.10.

2 · Reply

tommy45 Oct. 6 at 2:39 PM

$BTAI believe news soon for this company over sold stock here guys you could be looking at a 5 dollar plus stock soon here easy. gl rest of the week

1 · Reply

Mg_1970 Oct. 6 at 2:31 PM

$BTAI The levels are the same...

0 · Reply

Mg_1970 Oct. 6 at 2:16 PM

$BTAI I'm waiting like an idiot... 🤦‍♂️🙄 But when the fuck is this stock going to go up? I have always evaluated the stop in close and more or less it held that level, but now I'm tired 😡😡🙏

0 · Reply

FredoDog Oct. 6 at 2:08 PM

$BTAI Just in the typical lull between good news and FDA. This your first pharma stock or something? Some of you act like small children on caffeine and sugar. You'll either be rewarded or F'd depending on how the FDA answers, "Mother, may I?". Right now is nap time.

0 · Reply

DariHendrix Oct. 6 at 1:54 PM

$BTAI the money I have locked up in this is brutal -59% LOL give us some godly PR news pls

0 · Reply

dantes13 Oct. 6 at 1:50 PM

$BTAI look strong around 2.50,am back loaded and waiting couple months before this take off🍸❓️🤔

0 · Reply

Zappiys Oct. 6 at 3:57 AM

$BTAI

0 · Reply

Market Cap	40.50M
Revenue (ttm)	2.27M
Net Income (ttm)	-59.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,625.55%
Debt to Equity Ratio	-1.01

Volume	1,320,500
Avg Vol	12,309,908
Day's Range	N/A - N/A
Shares Out	16.01M
Stochastic %K	16%
Beta	0.18
Analysts	Sell
Price Target	$8.25